Actively Recruiting
18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma
Led by Rigshospitalet, Denmark · Updated on 2024-11-15
25
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study evaluating the positron-emitting radiopharmaceutical 18F-mFBG compared to 123I-mIBG scintigraphy for imaging of neuroblastoma
CONDITIONS
Official Title
18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- An established diagnosis of neuroblastoma based on tissue biopsy at any time before the trial; OR a presumed diagnosis based on symptoms, physical exam, imaging, lab, and genetic tests, including those already receiving treatment.
- The participant has had or will have a 123I-mIBG scan within 7 days before or after the 18F-mFBG scan, with no treatment between scans.
- The participant or legal guardian can understand and sign informed consent.
You will not qualify if you...
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark, 2100
Actively Recruiting
Research Team
L
Lise Borgwardt, MD, PhD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here